Biopsy‐Sparing Diagnosis of Coeliac Disease Based on Endomysial Antibody Testing and Clinical Risk Assessment
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Stiliano Maimaris und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Celiac Disease, Autoantibodies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Interest in a biopsy‐sparing diagnosis of coeliac disease in adults is growing.
Aims
To develop and prospectively validate a non‐invasive diagnostic strategy for adults with suspected coeliac disease based on clinical features and endomysial antibodies (EmA).
Methods
We retrospectively enrolled adults investigated for coeliac disease with EmA and duodenal biopsy between January 2000 and December 2021 in cohort 1 and stratified according to age at presentation (< 45 years; ≥ 45 years) and alarm symptoms. We evaluated diagnostic outcomes and accuracy of EmA. A prospective validation cohort was enrolled between Jan‐2022 and Dec‐2023 (cohort 2).
Results
Cohort 1 included 972 patients (641 F, mean age 42 ± 16); cohort 2 included 214 patients (145 F, 43 ± 18). In cohort 1, 35.4% were diagnosed with coeliac disease and 1.5% with non‐coeliac enteropathies. Of the coeliac disease diagnoses, 173 (50.3%) were in patients < 45 years old without alarm symptoms. No concomitant major organic disorders were diagnosed in patients with coeliac disease. EmA diagnostic accuracy was 99.1% (97.4% sensitivity; 100% specificity and PPV). Regarding non‐coeliac enteropathies, 87% were diagnosed among the 139 patients aged ≥ 45 years old with alarm symptoms and negative EmA. No non‐coeliac enteropathies were diagnosed in patients without alarm symptoms. Findings were confirmed in cohort 2.
Conclusions
Low‐risk adult patients could have been safely diagnosed with coeliac disease non‐invasively based on EmA without endoscopy and duodenal biopsy. Older patients with alarm symptoms should undergo endoscopy with duodenal biopsy to avoid missing non‐coeliac enteropathies. Further validation of our results is necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
- Istituti Clinici Scientifici Maugeri IRCCS, Gastroenterology Unit of Pavia Institute, Pavia, Italy.
- Department of Molecular Medicine, Unit of Anatomic Pathology, University of Pavia, Pavia, Italy.
- Unit of Anatomic Pathology, ICS Maugeri-IRCCS SpA SB, Pavia, Italy.
ORCID-Profile: Stiliano Maimaris, Annalisa Schiepatti, Giovanni Arpa, Chiara Scarcella, Federico Biagi
Zitieren
APA
Maimaris, S., Schiepatti, A., Conforme Torres, D. I., Muscia, R., Gregorio, V., Delogu, C., Parisi, I. M., Dota, M., Arpa, G., Cicalini, C., Massetti, G., Scarcella, C., Minerba, P., & Biagi, F. (2025). Biopsy‐Sparing Diagnosis of Coeliac Disease Based on Endomysial Antibody Testing and Clinical Risk Assessment. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70129
Vancouver
Maimaris S, Schiepatti A, Conforme Torres DI, Muscia R, Gregorio V, Delogu C, et al. Biopsy‐Sparing Diagnosis of Coeliac Disease Based on Endomysial Antibody Testing and Clinical Risk Assessment. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70129
BibTeX
@article{Maimaris2025,
author = {Maimaris, Stiliano and Schiepatti, Annalisa and Conforme Torres, Daniel Ignacio and Muscia, Roberta and Gregorio, Virginia and Delogu, Claudia and Parisi, Ignazio Marzio and Dota, Michele and Arpa, Giovanni and Cicalini, Carolina and Massetti, Giulio and Scarcella, Chiara and Minerba, Paolo and Biagi, Federico},
title = {Biopsy‐Sparing Diagnosis of Coeliac Disease Based on Endomysial Antibody Testing and Clinical Risk Assessment},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70129}
}
EUVIMED